Polaryx Therapeutics Inc (PLYX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.00+0.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PLYX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PLYX — officer change
Dated 2026-07-21
Chief Medical Officer — Lisa Bollinger, MD: Dr. Lisa Bollinger resigned from her position as Chief Medical Officer.
Why it matters: Fast Track Designation can speed up the development of PLX-200. It signals regulatory support for the drug's potential.
Supportive ifThe FDA confirms continued support for PLX-200 across all four planned indications.
Worry ifThe FDA withdraws or questions the Fast Track Designation.
Why it matters: Effective strategies can improve cash flow and reduce losses. This could boost investor confidence.
Supportive ifManagement announces a new plan to improve cash flow.
Worry ifNo updates or plans shared by management regarding cash flow.
Why it matters: News about the private placement can change liquidity and how investors feel.
Watch forThe money from the private placement will be used for operations.
Also watch forNo updates on the use of funds or delays in the capital raise.
Why it matters: The $10 million from the PIPE financing is crucial for funding the SOTERIA trial. Effective use of these funds is vital.
Watch forThe company shows progress in clinical goals funded by the PIPE financing.
Also watch forThe company misses clinical goals because of poor use of the PIPE financing.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$382 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $2,348 loss on $10,000 · 23.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,466 loss on $10,000 · 94.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Ongoing negative cash flow shows financial stress. It also shows poor cash management.
Worry ifQ2 cash flow from operations reported worse than -$2 million.
Less concerning ifQ2 cash flow from operations reported better than -$2 million.
Why it matters: Early data will show if PLX-200 works well and is safe. Good results may bring more money.
Supportive ifThe SOTERIA trial data shows it is safe and works well.
Worry ifData shows PLX-200 is not safe or effective.
Why it matters: Higher losses mean worse cash flow. This can hurt investor confidence.
Worry ifQ2 losses reported over $2 million.
Less concerning ifQ2 losses reported under $2 million.
Why it matters: This may impact cash flow and funding. Investors will check how well it works.
Watch forGood market response or more funding after placement.
Also watch forBad market response or no clear effect on operations.
Why it matters: Starting the SOTERIA trial is key for testing PLX-200 in rare diseases. It shows progress in clinical development.
Supportive ifThe SOTERIA trial starts as planned in Q4 2026.
Worry ifThe trial launch is delayed past Q4 2026.